PREVALENCE AND ANTIBIOTIC SUSCEPTIBILITY OF ACINETOBACTERIN A TERTIARY CARE HOSPITAL IN CHENNAI, INDIA
Objective: The present study is to determine the prevalence and antibiotic susceptibility of Acinetobacter species in samples collected from patients in tertiary care hospital in Chennai.
Methods: A total of17,827patient’s clinical samples were collected from various wards and ICUs of Saveetha Medical College and Hospital, Chennai, Tamilnadu over a period of 7 mo [between January 2020 and July 2020]. All samples were tested in the microbiology lab of Saveetha Medical College and Hospital using standard operating procedures.
Results: Out of 17,827 samples, 2,816 were culture positive. 122 of the isolates tested positive for Acinetobacter spp.and 81.1% of the isolates belonged to Acinetobacterbaumannii. Most of the infection occurred in the age group of 21-40 y and predominantly in female patients (female, male ratio 1.9:1).General wards contributed to 54.9% of the Acinetobacter infection, followed by ICU(27%) and OPD(18%). Maximum isolates were recovered from urine(34.4%) and endotracheal secretions(29.5%).60.7% of the Acinetobacterspp were multidrug-resistant(MDR)i.e. resistant to more than 3 antibiotic group.In our study, most Acinetobactersppwere resistant to penicillin(46-100%), third and fourth generation cephalosporin (36-61.5%), carbapenems (34.4-82.8%)and quinolones(39.3-46.7%). None of the isolates were resistant to colistin. 93.4% ofisolates were sensitive to tigecycline and 87.7% sensitive to amikacin.
Conclusion: Our study observed a high incidence of MDR inAcinetobacterspp, which is in line with most of the research findings in recent times. Most of Acinetobacterspp were resistant to penicillin, third and fourth generation cephalosporins, quinolones, carbapenems,which is alarming as it leaves fewer options for the line of treatment. Some strains were sensitive to cefepime, ceftazidime, piperacillin-tazobactam, levofloxacin, imipenem and meropenem. Considering the increasing MDR nature of Acinetobacterspp a combination of the former along with colistin, tigecycline, amikacin(which have shown more than 85% sensitivity) would need to be studied.Also, strict measures to control the spread of Acinetobacter infection, better management of antibiotics usage and newer therapeutic option for treatment need to be looked at.
2. Michael J McConnell, Luis Actis, JeronimoPachon.Acinetobacterbaumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 2013;37:130-55.
3. Uwingabiye J, Lemnouer A, Baidoo S. Intensive care unit-acquired Acinetobacterbaumannii infections in a moroccan teaching hospital: epidemiology, risk factors and outcome. Germs 2017;7:193-205.
4. Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis 2010;2:291-304.
5. Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A. (eds). Mackie and McCartney practical medical microbiology. 14thedn. Edinburgh: Churchill; 1996. p. 131-51.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. Wayne, Pennsylvania: Clinical and Laboratory; 2020.
7. Rit K, Saha R. Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital. Niger Med J 2012;52:126-8.
8. Gupta N, Gandham N, Jadhav S, Mishra RN. Isolation and identification of Acinetobacterspecies with special reference to antibiotic resistance. J Nat SciBiol Med 2015;6:159-62.
9. Sharma RK, Mamoria VP. A prospective study on prevalence and antibiotic susceptibility pattern of Acinetobacterbaumannii in clinical samples obtained from patients admitted in various wards and intensive care units. J Mahatma GandhiUniv Med Sci Tech 2017;2:122-7.
10. Bhattacharyya S, Bhattacharyya I, Rit K, Mukhopadhyay PK, Dey JB, Ganguly U, et al. Antibiogram of Acinetobacter spp. isolated from various clinical specimens in a tertiary care hospital in West Bengal, India. Biomed Res 2013;24:43-6.
11. Saha S, Devi KM, Damrolien S, Devi KS. A study of acinetobacter infection in a tertiary care hospital in Northeast India. Int J Res Med Sci 2018;6:2076-80.
12. Sivaranjani V, Umadevi S, Srirangaraj S, Kali A, Seetha KS. Multi-drug resistant Acinetobacter species from various clinical samples in a tertiary care hospital from South India. AMJ 2013;6:12, 697-700.
13. E BergogneBerezin, K J Towner.Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. ClinMicrobiol Rev 1996;9:148–65.
14. Jagii N, Sissodia P, Sharma L.Acinetobacterbaumannii isolates in a tertiary care hospital: antimicrobial resistance and clinical significance. J Microbiol Infectious Diseases 2012;2:57-63.
15. Ali?kan H, Colakoglu S, Turunç T. Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and acinetobacterbaumannii strains isolated from patients in intensive care unit and inpatient clinics. MikrobiyolBul 2008;42:321-9.
16. Shanthi M, Sekar U. Multi-drug resistant pseudomonas aeruginosa and Acinetobacterbaumannii infections among hospitalized patients: risk factors and outcomes. J Assoc Physicians India 2009;8:687–93.
17. Queenan AM, Pillar CM, Deane J. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from capital surveillance 2010. DiagnMicrobiol Infect Dis 2012;73:267-70.
18. Lazureanu V, Porosnicu M, Gandac C, Moisil T, Baditoiu L, Laza R, et al. Infection with Acinetobacterbaumannii in an intensive care unit in the Western part of Romania. BMC Infect Dis 2016;(16 Suppl 1):95.
19. Broek PJ, Van Der Reijden TJK, Van Strijen E, HelmigSchurter AV, Bernards AT, Dijkshoorn L. Endemic and epidemic Acinetobacter species in a university hospital: an 8 y survey. J ClinMicrobiol 2009;47:3593–9.
20. Sohail M, Rashid A, Aslam B, Waseem M, Shahid M, Akram M, et al. Antimicrobial susceptibility of Acinetobacterclinical isolates and emerging antibiogram trends for nosocomial infection management. Rev Soc Bras Med Trop 2016;49:300-4.
21. Sader SH, Carvalhaes GC, Streit MG, Castanheira M, Flamm KR. Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. IntJ Infectious Diseases 2020;91:32–7.
22. Lai CC, Chen CC, Lu YC, Chuang YC, Tang HJ. In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacterbaumannii and pseudomonas aeruginosa. Infect Drug Resist 2018;12:25-9.
23. Turk Dagi H, Kus H, Arslan U, Tuncer I. In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacterbaumannii isolates. MikrobiyolBul 2014;48:311-5.
24. Turner PJ, Greenhalgh JM. MYSTIC study group (Europe) the activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. ClinMicrobiol Infect 2003;9:563–7.
25. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenemyearly susceptibility test information collection) 2006 results. DiagnMicrobiol Infect Dis 2008;60:185-92.
26. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacterbaumannii. Antimicrob Agents Chemother2007;51:3471–84.
27. Joel Fishbain, Anton Y Peleg. Treatment of acinetobacter infections.Clin Infectious Diseases 2010;51:79–84.
28. Dash M, Padhi S, Patnaik S, Mohanty I, Misra P. Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna J Med 2013;3:97–102.
29. Adams Haduch JM, Paterson DL, Sidjabat HE. Genetic basis of multidrug resistance in Acinetobacterbaumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008;52:3837-43.
30. Yau W, Owen RJ, Poudyal A.Colistinheteroresistance in multidrug-resistant Acinetobacterbaumannii clinical iso¬lates from the western pacific region in the SENTRY antimi¬crobial surveillance programme. J Infect 2009;58:138-44.
31. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacterbaumannii isolates. J AntimicrobChemother 2006;58:1099-100.
32. KnamSooKo, JiYoeunSuh, Ki Tae Kwon. High rates of resistance to colistin and polymixin B in subgroups of Acinetobacterbaumannii isolates from Korea. J AntimicrobChemother 2007;60:1163-7.
33. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacterbaumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32:29-32.
34. Wei W, Yang H, Hu Lifen, Ye Ying,Li Jiabin. Activity of levofloxacin in combination with colistin against Acinetobacterbaumannii: in vitro and in a galleria mellonella model. J MicrobiolImmunol Infection 2017;50:821-30.
This work is licensed under a Creative Commons Attribution 4.0 International License.